Introduction {#s1}
============

Schizophrenia spectrum disorders (SSD) are heterogeneous syndromes with well-established risk factors including exposure to childhood adversity, cannabis use during adolescence, a history of obstetric complications, stressful events during adulthood, and low maternal serum folate level ([@B1]). In recent years, there has been a growing interest in tobacco smoking as a risk factor for SSD ([@B2], [@B3]).

Tobacco smoking is known to cause a wide range of physical health problems. It is the leading cause of preventable death, through increasing the risk of lung and other malignancies, chronic obstructive pulmonary disease (COPD), coronary heart disease, cerebrovascular disease, asthma and diabetes ([@B4]). Two systematic reviews and meta-analyses have examined the association between tobacco smoking and psychotic disorders ([@B2], [@B3]). In pooling longitudinal studies (*n* = 5), Gurillo and colleagues reported a 2-fold increase in the risk of incident psychotic disorders in people who were daily tobacco smokers compared to those who were not (RR = 2.18; 95% CI 1.23--3.85). Similarly, Hunter et al. ([@B3]) who pooled data from studies identified using inclusion criteria with the outcome restricted to schizophrenia (*N* = 5) also reported smoking tobacco was associated with a 2-fold risk of schizophrenia (RR = 1.99; 95% CI 1.10--3.61). Both studies concluded that further research was needed to examine the potential causal role of tobacco smoking in the onset of SSD.

The association between tobacco smoking and SSD is of growing significance. There is evidence that nicotine alters signaling in the dopaminergic, cholinergic, and glutamatergic neurotransmitter systems, particularly in adolescence ([@B5]). Whilst the smoking of tobacco by young people has declined in many high income countries, there has been an increase in exposure to nicotine by this demographic through the availability of e-cigarettes ([@B6]). It is therefore important to critically examine the evidence for a causal relationship between tobacco smoking and SSD.

In this review we aimed to evaluate the relationship between tobacco smoking and SSD which we defined as any non-affective psychotic disorder against causal criteria based on the Bradford Hill Framework ([@B7], [@B8]). The Bradford Hill Framework provides nine criteria for establishing a causal relationship between an exposure and outcome. This review examined longitudinal studies identified from the two recent systematic reviews of tobacco smoking and incident SSD and other identified studies. The evidence for a causal relationship between tobacco smoking and SSD, alternative explanations for the association and the health implications are discussed.

Methods {#s2}
=======

Literature search
-----------------

We used the results of the two recently conducted systematic reviews ([@B2], [@B3]) to identify studies which examined tobacco smoking as an exposure and SSD as an outcome. As the review by Hunter et al. ([@B3]) restricted the outcome to a diagnosis of schizophrenia, we used the broader search strategy of Gurillo et al. ([@B2]) to identify studies from January 2014 to May 2018 that included the broader outcome of psychosis. These psychosis outcomes included schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, non-affective psychotic disorder, atypical psychosis, psychotic depression, and bipolar mania with psychotic features.

The inclusion criteria of the current review were: (a) longitudinal case control or cohort studies; (b) study populations of participants with psychosis or schizophrenia as the outcome (defined as those who meet the diagnostic criteria by structured interview or diagnosed by treating clinician); (c) presence of tobacco smoking prior to psychosis or schizophrenia diagnosis. Studies which were cross sectional in design or only provided sub-diagnostic outcomes of psychosis (e.g., psychotic symptoms, hallucinations, delusions) were excluded.

Data extraction
---------------

Titles and abstracts of the articles were reviewed to identify studies that met the eligibility criteria. The following characteristics were extracted from each study when available: (a) study methodology (including author, publication year, location, study design, follow-up period, sample numbers, loss to follow-up, age at baseline, tobacco smoking measures, and assessment of psychosis or schizophrenia), and (b) study findings (effect size metrics, 95% CI, and confounders adjusted for).

The quality or the studies assessing for risk of bias was evaluated using Newcastle--Ottawa Scale (NOS) ([@B9]) as shown in Supplementary Table [1](#SM1){ref-type="supplementary-material"}. The NOS is a method recommended by the Cochrane Non-randomized Studies Methods Working Group to evaluate the quality of the study. Points are assigned based on the selection process of cohorts (0--4 points), the comparability of the cohorts (0--2 points) and the identification of the exposures and the outcomes of research participants (0--3 points). A score of 7 or greater out of 9 was defined as high quality. Studies were assessed independently by two reviewers (LM and JS).

Assessment of causality
-----------------------

Studies that met inclusion and exclusion criteria were assessed using causal criteria based on the Bradford Hill Framework shown in Supplementary Table [2](#SM2){ref-type="supplementary-material"}. Of the nine criteria, five were chosen as most relevant for the purposes of this study (strength of association, consistency, temporality, dose-response, and biological plausibility). Given that smoking is known to cause a wide range of health problems, the criteria of specificity was not applicable. No studies have performed experimental manipulation exposing adolescents to tobacco because of the known harmful effects therefore this criteria was not included. Coherence was not included because of the lack of homogenous pathology evident in psychosis. In relation to analogy, the association between cannabis use and psychosis, reported to be causal ([@B1]) has some analogy to that of tobacco and psychosis. However, it is widely recognized that adolescents who smoke tobacco are more likely to smoke cannabis ([@B10]--[@B12]). Thus, cannabis rather than being analogous to tobacco in its relationship with psychosis may in fact be an important confounder. Similarly there are other important environmental factors which might confound the relationship between tobacco smoking and incident psychotic disorder. To address this concern, for the purpose of assessing evidence of causality, we included an extra criteria "accounted for confounding." These six criteria were deemed appropriate by the research team in order to grade the associations reported between adolescent tobacco smoking and future risk of SSD as a basis for causality discussion ([@B7]).

Results {#s3}
=======

Gurillo and colleagues ([@B2]) identified four studies which met the specified inclusion criteria ([@B13], [@B14], [@B15], [@B16]). One of the longitudinal studies ([@B17]) which they included in their pooled analysis did not determine the presence of tobacco smoking before the schizophrenia diagnosis and was therefore excluded. Hunter et al. ([@B3]) included another study ([@B18]) and the updated search identified a further three studies which met inclusion criteria ([@B13], [@B19], [@B20], [@B21]). In total, eight studies (seven cohort and one case-control studies) were included for assessment of a causal relationship between tobacco smoking in adolescence and incident SSD. Using the NOS, all seven cohort studies scored 7/9 or greater demonstrating they were of high quality (Table [1](#T1){ref-type="table"}).

###### 

Assessment of study quality using the Newcastle Ottowa Scale[^\*^](#TN1){ref-type="table-fn"}.

  **Criteria**                                                               **Kendler et al. ([@B13])**   **Mustonen et al. ([@B21])**   **McGrath et al. ([@B19])**   **Sørensen et al. ([@B15])**   **Weiser et al. ([@B14])**   **Wium-Andersen et al. ([@B18])**   **Zammit et al. ([@B16])**
  -------------------------------------------------------------------------- ----------------------------- ------------------------------ ----------------------------- ------------------------------ ---------------------------- ----------------------------------- ----------------------------
  Representativeness of exposed cohort                                       \+                            \+                             \+                            \+                             \+                           \+                                  \+
  Selection of non-exposed cohort                                            \+                            \+                             \+                            \+                             \+                           \+                                  \+
  Ascertainment of exposure                                                  \+                            --                             --                            \+                             --                           --                                  --
  Demonstration that outcome of interest was not present at start of study   \+                            \+                             \+                            \+                             \+                           \+                                  \+
  Comparability of cohorts on basis of design and analysis                   ++                            ++                             ++                            \+                             \+                           \+                                  ++
  Ascertainment of outcome                                                   \+                            \+                             \+                            \+                             \+                           \+                                  \+
  Follow-up adequate for outcome to occur                                    \+                            \+                             \+                            \+                             \+                           \+                                  \+
  Adequacy of follow-up of cohorts                                           --                            --                             --                            --                             \+                           \+                                  --
  Total Score                                                                8/9                           7/9                            7/9                           7/9                            7/9                          7/9                                 7/9

*A score of 7/9 or greater represents a high-quality study*.

Study characteristics
---------------------

Table [2](#T2){ref-type="table"} summarizes the study characteristics. They utilized birth cohort studies of offspring ([@B19], [@B21]) or mothers ([@B15]), cohorts of young male conscripts from defense forces ([@B14], [@B16]), two cohorts combined, the first consisting of mothers recruited from a birth cohort, the second were male conscripts Kendler et al. ([@B13]) and two general population cohorts to assess cardiovascular risk factors ([@B18]). The longitudinal case control study was of participants at clinical high risk of psychosis ([@B20]). All studies were from high income countries. The follow-up period of all cohort studies was adequate to ascertain incident cases of SSD, ranging from a minimum of 4 years ([@B14]) to a maximum of 48 years ([@B15]). Two of the studies were genetically informed with one examining psychosis risk in family members discordant for smoking ([@B13]), the other examining schizophrenia in people with different alleles of the rs1051730 genotype in the nicotinic acetylcholine receptor gene stratified by smoking status ([@B18]).

###### 

Longitudinal studies examining the association between tobacco smoking and later schizophrenia and related disorders.

  **Reference (Country and Methodology)**                                                                                                     **Sample size (psychosis prevalence)**                                                       **Diagnoses and how they were ascertained**                                                                                                            **Definition of smoking (prevalence of smoking)**                                                                                                       **Length of follow-up**                    **Results (95% CI)**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       **Covariates**                                                                                                                                                                                                        **Interpretation**
  ------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------ ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Buchy et al. ([@B20]) (USA; Prospective Case-Control study)                                                                                 362 Clinical High Risk participants (90 transitioned to psychosis over 2 years)              Any psychotic disorder or a rating of ≥6 on any positive symptom of Scale of Prodromal Symptoms                                                        At least occasionally                                                                                                                                   2 years                                    Baseline tobacco use (frequency or severity) was not different between those participants who later transitioned to psychosis (*n* = 90) from those without transition (*n =* 272). Cannabis and alcohol use were not associated with psychosis transition.                                                                                                                                                                                                                                                Demographic variables, cannabis use, alcohol use, cocaine, opiates, other substances                                                                                                                                  Tobacco, alcohol and cannabis use (frequency or severity) were not associated with increased risk of transition to psychosis. The prevalence of tobacco and cannabis dependence were very low in this cohort with likely inadequate power to examine these longitudinal associations.
  Kendler et al. ([@B13]) (Two Swedish Cohorts using birth and conscript registries)                                                          1,413,849 women and 233,879 men                                                              Schizophrenia and non-affective psychosis (ICD)                                                                                                        At least 1 cigarette/day (NA)                                                                                                                           Females 18.5 years, males 7.9 years        Increased risk of subsequent schizophrenia in females who were light smokers (1--9 cigarettes/ day: HR = 2.21; 95% CI 1.90--2.56) and for heavy smokers (≥10 cigarettes/day) (HR = 3.45; 95% CI 2.95--4.03). Increased risk of subsequent schizophrenia for male light smokers (HR = 2.15; 95% CI 1.25--3.44) and for heavy smokers: HR = 3.80; 95% CI 1.19--6.60). Increased risk persisted after adjusting for covariates and was present in monozygotic twins who were discordant for smoking status.   Neighborhood and parental socioeconomic status, prior drug abuse, psychosis prodrome, family-level and community-level socioeconomic status and genetic liability to psychosis                                        Cigarette smoking increased the risk of schizophrenia in a dose response fashion. The association cannot be attributed to incident smoking in the prodromal phase. Accounting for genetic disposition using monozygotic twins discordant for smoking resulted in an attenuation of the association however it was still significant suggesting the relationship between smoking cigarettes and future schizophrenia risk is only partially explained by shared risk genes.
  McGrath et al. ([@B19]) (Australia: Mater University of Queensland Birth Cohort (MUSP)                                                      2,441 of whom 65 (2.6%) received a diagnosis of psychosis                                    Non-affective psychotic disorder based on the Composite International Diagnostic Interview                                                             Age at first tobacco use self-reported at 21 years. Participants grouped into age of tobacco use ≤ 15 years (24.1%), 16--21 years (25.8%) and no use.   6 years                                    Early onset tobacco use was associated with non-affective psychosis after adjusting for age and sex (OR 3.1; 95% CI 1.8-5.6). After excluding those with a history of cannabis use, the association attenuated (OR 1.9; 95% CI 0.09--4.3).                                                                                                                                                                                                                                                                 Age, sex and cannabis use                                                                                                                                                                                             Early onset tobacco use was associated with later psychosis. The loss of significance of this relationship after excluding those with a history of cannabis use may be attributed to a loss of power as the direction of the relationship (positive association) remained.
  Mustonen et al. ([@B21]) (Northern Finland Birth Cohort; 1986)                                                                              6,081 of whom 110 (1.8%) developed psychosis                                                 Any psychotic disorder (ICD) based on clinical diagnoses from hospital summaries, primary health care and specialists                                  At least 1 cigarette/day (12.3%)                                                                                                                        14 years                                   Smoking 1--9 cigarettes/ day was not associated with psychosis. Smoking ≥ 10 cigarettes/day was associated with increased risk of psychosis (Unadjusted HR = 3.15, 95% CI 1.94--5.13; Fully adjusted HR = 2.00, 95% CI 1.13--3.54). A dose--response was reported with a positive trend test (fully adjusted OR = 1.05; 95% CI: 1.01--1.08).                                                                                                                                                               Prodromal symptoms, Cannabis use, alcohol use, other substance use, parental substance abuse, parental psychosis                                                                                                      Smoking cigarettes was associated with an increased risk of psychosis after adjusting for a wide range of covariates. There was a dose response relationship between smoking cigarettes and future risk of psychosis.
  Sørensen et al. ([@B15]) (Denmark; Mothers from the Copenhagen Perinatal Cohort)                                                            7926 of whom 309 (3.9%) developed schizophrenia spectrum disorder                            Diagnosis of Schizophrenia spectrum disorder (schizoaffective disorder, schizophrenia, schizophrenia-like psychosis) in the Danish National Registry   At least 1 cigarette/day (52.1%)                                                                                                                        46--48 years                               There was an association between smoking and increased risk of subsequent schizophrenia spectrum disorder: (OR and 95% CI 1.42; 1.12--1.80). There was a linear effect of smoking (1.18; 1.07--1.30).                                                                                                                                                                                                                                                                                                      Age, social status, psychopharmacological treatment at baseline                                                                                                                                                       Cigarette smoking in women attending antenatal care increased the risk of subsequent schizophrenia spectrum disorder in a dose response fashion.
  Weiser et al. ([@B14]) (Young Male Cohort (16--17 years) from the Israel Defence Force)                                                     14,248 of whom 44 (0.3%) were hospitalized for schizophrenia                                 Hospitalized with an ICD 10 diagnosis of Schizophrenia                                                                                                 At least 1 cigarette/day (28.4%)                                                                                                                        4-16 years (mean = 10.2 years, SD = 3.6)   Those who smoked at least one cigarette/ day were at increased risk of schizophrenia (adjusted relative risk = 1.94, 95% CI 1.05--3.58). There was a significant linear association between number of cigarettes smoked and risk of schizophrenia where smoking increased risk of subsequent schizophrenia.                                                                                                                                                                                                Non-psychotic psychiatric disorder, below-normal social or intellectual functioning in adolescence and socioeconomic status                                                                                           Cigarette smoking in young adult males increased the risk of schizophrenia. A dose response relationship was reported.
  Wium-Andersen et al. ([@B18]) (Two General Danish Population Cohorts: Copenhagen General Population Study and Copenhagen City Heart Study   63,296 (0.1% hospitalized for schizophrenia and 6% had purchased antipsychotic medication)   ICD diagnoses of Schizophrenia and purchasing of antipsychotic medication obtained from the national Danish Patient Registry.                          Ever smoked (63%), Cigarettes/ day and pack-years calculated from a self-report questionnaire.                                                          3--21 years                                Compared with never-smokers, participants smoking \>20 cigarettes/day had an increased risk of schizophrenia (adjusted OR and 95% CI 6.18; 2.77--13.8).                                                                                                                                                                                                                                                                                                                                                    Alcohol use, weekly physical activity, level of education after lower secondary school, basic vocational training, level of income, civil status, plasma levels of C-Reactive Protein and comorbid physical illness   Smoking tobacco was associated with higher risk of schizophrenia and antipsychotic medication use. The rs1051730 genotype in the nicotinic acetylcholine receptor gene was associated with psychosis outcomes in the ever smokers but not the never smokers suggesting a causal relationship between cigarettes and psychosis outcomes.
  Zammit et al. ([@B16]) (Cohort of males conscripted into the Swedish army between 1969 and 1970)                                            50,053 of whom 363 (0.7%) were diagnosed with schizophrenia                                  ICD Diagnoses of schizophrenia and other psychoses extracted from the Swedish National Register of Inpatient Care                                      At least 1 cigarette/day (59%)                                                                                                                          27 years                                   There was no association between any daily smoking and subsequent schizophrenia (adjusted Hazard Ratio (aHR) 0.8, 95% CI 0.7--1.1). Those who smoked ≥ 20 cigarettes/ day were less likely to develop schizophrenia (aHR 0.5; 95% CI 0.3--0.9) and there was a significant linear trend where smoking decreased the risk of subsequent schizophrenia (aHR 0.8; 95% CI 0.7--0.9).                                                                                                                           Cannabis and drug use, poor social integration, disturbed behavior, IQ, place of upbringing, family economy, and family psychiatric history                                                                           After adjusting for potential confounders, there was a decrease in the risk of schizophrenia in people who smoked cigarettes. There was a dose response reduction with those who smoked the most cigarettes having the lowest risk of schizophrenia.

Assessment of studies against bradford hill criteria
----------------------------------------------------

Using causal criteria, based on the Bradford Hill Framework Hill ([@B8]), of the eight studies examined, six reported a positive association between tobacco smoking and risk of schizophrenia spectrum disorder. The strength of the associations were robust ranging from an almost 50% increased risk ([@B15]) to a 6-fold increased risk of schizophrenia in heavy smokers ([@B18]). In these six studies, all reported a temporal association with appropriate adjustment for confounding variables, particularly comorbid substance use. All but one ([@B19]) demonstrated a dose response relationship between tobacco use and SSD. By contrast, one study ([@B16]) reported that smoking tobacco reduced the risk of schizophrenia and the case control study ([@B20]) found no association.

Discussion {#s4}
==========

Two meta-analyses have demonstrated that smoking tobacco is associated with a 2-fold increase in risk of incident schizophrenia ([@B3]) or broader psychosis ([@B2]). Based on these systematic reviews and our own literature search, we identified eight studies that examined the longitudinal association between tobacco smoking and incident SSD of which six demonstrated a positive association ([@B13]--[@B15], [@B18], [@B19], [@B21]), one a negative association ([@B16]) and the final study showed no association ([@B20]). Using the Bradford Hill framework, a causal association between tobacco smoking and onset of SSD is discussed on the basis of strength of association, temporality, dose-response, adjustment for confounding factors, biological plausibility, and consistency of the association.

Strength
--------

Of the six studies that found a positive association ([@B13]--[@B15], [@B18], [@B19], [@B21]), five reported moderate to large effect sizes ([@B22]) (Tables [2](#T2){ref-type="table"}, [3](#T3){ref-type="table"}) consistent with a causal relationship ([@B8]). Sørensen et al. ([@B15]) reported a smaller effect size with a 42% increase in the odds of schizophrenia spectrum disorder in people who smoked cigarettes.

###### 

Assessment of studies against Bradford Hill criteria.

  **References**                  **Strength of Association**                                                                                                       **Temporality**                   **Dose-response**                                                                                    **Confounding**
  ------------------------------- --------------------------------------------------------------------------------------------------------------------------------- --------------------------------- ---------------------------------------------------------------------------------------------------- ---------------------
  Buchy et al. ([@B20])           No Association                                                                                                                    Not examined                      Not examined                                                                                         Limited adjustment
  Kendler et al. ([@B13])         Smoking cigarettes was associated with a twofold (light smokers) to threefold (heavy smokers) increase in risk of schizophrenia   Yes, longitudinal cohort study.   Yes                                                                                                  Adequately adjusted
  McGrath et al. ([@B19])         Smoking cigarettes before age of 15 was associated with a threefold risk of psychosis                                             Yes, longitudinal cohort study.   Not examined                                                                                         Adequately adjusted
  Mustonen et al. ([@B21])        Smoking ≥10 cigarettes/day was associated with an almost threefold increased risk of psychosis                                    Yes, longitudinal cohort study.   Yes                                                                                                  Adequately adjusted
  Sørensen et al. ([@B15])        Smokers had a 42% increase in risk of incident schizophrenia spectrum disorder                                                    Yes, longitudinal cohort study.   Yes                                                                                                  Adequately adjusted
  Weiser et al. ([@B14])          Smoking cigarettes had a twofold risk in incident schizophrenia                                                                   Yes, longitudinal cohort study.   Yes                                                                                                  Adequately adjusted
  Wium-Andersen et al. ([@B18])   Smoking ≥20 cigarettes/day had a six fold risk of developing schizophrenia                                                        Yes, longitudinal cohort study.   Yes                                                                                                  Adequately adjusted
  Zammit et al. ([@B16])          Smoking ≥20 cigarettes/day had a 50% reduction in risk of developing schizophrenia                                                Yes, longitudinal cohort study.   There was a significant linear trend where smoking decreased the risk of subsequent schizophrenia.   Adequately adjusted

*Green, supportive of causal association; Yellow, not examined or not applicable; Red, no association or negative association*.

Consistency
-----------

Consistency of the association is assessed through multiple studies of independent cohorts confirming the same result. In the eight longitudinal studies, six reported a positive association between tobacco smoking and incident SSD. Of the two which did not report a positive association, one was a case-control study of participants at clinical high risk for psychosis which found that neither tobacco nor cannabis smoking were associated with transition to psychosis. The prevalence of tobacco and cannabis dependence in this cohort was low and the study may have been underpowered to examine the effects of these substances on transition to psychosis. Zammit et al. ([@B16]) reported that smoking tobacco was associated with a lower risk of future schizophrenia, and was therefore inconsistent with the main body of research. The overwhelming majority of studies showed a positive relationship fulfilling criteria for consistency.

Temporality
-----------

The six studies that reported a positive association demonstrated a clear temporal relationship with the exposure of tobacco smoking preceding the onset of SSD. Schizophrenia spectrum disorders frequently have an insidious onset with a long prodrome. In order to address this concern, ([@B21]), adjusted for prodromal psychotic symptoms at baseline and Kendler et al. ([@B13]) accounted for the possible prodrome by conducting a subanalysis restricting the onset of SSD to at least 5 years following initial exposure to tobacco. The relationship between tobacco smoking and onset of schizophrenia was largely attenuated after accounting for the prodrome rendering reverse causality an unlikely explanation for the association between tobacco use and SSD thus suggesting tobacco smoking precedes the illness.

Dose-response
-------------

A dose response between tobacco smoking and incident SSD was reported in five of the six studies reporting a positive association. In three studies ([@B14], [@B15], [@B21]) a significant linear trend was demonstrated where the risk of SSD increased with the an increase in tobacco smoking. In two studies ([@B13], [@B18]), those who smoked more daily tobacco had an increase in the odds of developing SSD.

Potential confounders
---------------------

The relationship between tobacco use and SSD remained significant even after adjusting for factors that might confound the relationship including family socio-economic status, cannabis use ([@B1]), parental substance abuse and parental psychosis ([@B23]--[@B27]). A shared genetic liability was also accounted for in two genetically informed studies ([@B13], [@B18]). Adjustment for confounders attenuated the strength of the association but significance was maintained in all but one study ([@B19]), probably due to a lack of power for the analysis. None of the studies adjusted for childhood trauma ([@B28]).

Biological plausibility
-----------------------

Tobacco and tobacco smoke contain almost 5,000 different chemicals. Nicotine is the most important pharmacologically active and psychotogenic compound in tobacco smoke because of its interaction with nicotinic acetylcholine receptors ([@B29]). Previous reports on tobacco smoking suggests that nicotine could alter signaling of dopaminergic, cholinergic, and glutamatergic neurotransmitter systems ([@B5], [@B30]) and thus could potentially influence brain development as suggested by studies of adolescent nicotine exposure and neurodevelopmental trajectories ([@B5]). Also, excess nicotine intake during early adolescence is associated with abnormal white matter maturation in adults ([@B31]), and chronic cigarette smoking has been linked to structural brain changes such as gray matter decreases in the prefrontal cortex, which correspond with areas where functional alterations occur from nicotine exposure ([@B32]).

Furthermore, recent evidence suggest that adolescent nicotine use could have persistent effects on nicotine receptor responsiveness, which results in the strengthening of negative emotional changes and alterations in cognitive functioning ([@B5]).

Alternative explanations
------------------------

There are other explanations for the positive association between tobacco smoking and SSD. Individuals who develop schizophrenia are more likely to have externalizing symptoms in childhood and adolescence ([@B33], [@B34]) and children with externalizing symptoms are more likely to smoke tobacco during adolescence ([@B35]). There may be unmeasured confounding. None of the studies adjusted for childhood trauma, a well-established risk factor for SSD ([@B1], [@B28]) and for tobacco use ([@B36]). Similarly there was no adjustment for prenatal tobacco smoking exposure which is associated with both an increased risk of smoking in adolescence ([@B37]) and an increased risk of schizophrenia even after adjusting for life time smoking ([@B3], [@B38]). Furthermore, recent studies have suggested bidirectional associations by revealing single nucleotide polymorphisms associated with nicotine dependence (CHRNA5) that are also associated with schizophrenia ([@B39], [@B40]).

Limitations {#s5}
===========

Each study included in this review is observational in methodology, and the majority of cohort studies included had significant attrition. Participants who are most likely to be lost to follow up are more likely to be socioeconomically disadvantaged and be at increased risk of both tobacco smoking and mental illness. Therefore, it is unlikely that attrition would significantly affect reported associations. Measurement of tobacco smoking has been measured via self-report or by interview, generally at one point in time and often retrospectively recalled. Only one study measured the long-term smoking exposure prior the psychotic illness using pack-years ([@B18]) which provides a more precise measurement of tobacco smoke exposure. Further, no studies have used biological markers for tobacco smoking such as expired air carbon monoxide ([@B41]) or serum cotinine measurement ([@B42]). These limitations are inherent to large cohort and registry studies and are difficult to overcome. Finally, as two recent systematic reviews had been published on this topic, we relied on these to identify the studies included in this review rather than replicating the searches in these studies.

Implications
------------

Given tobacco is known to have widespread adverse health outcomes and governments around the world are adopting policies to reduce tobacco smoking, why is it important to clarify if smoking tobacco has a causal role in the onset of SSD? The first reason is that better understanding the aetiopathogenesis of SSD will inform our knowledge of this syndrome which may lead to better treatments. The second, a much more urgent consideration is the growing availability of electronic (e) cigarettes. These have been developed as a safer alternative to cigarettes by enabling nicotine use without the exposure to carcinogenic chemicals associated with smoking tobacco.

However, there is growing use of e-cigarettes and other nicotine products by adolescents ([@B6]) and it is acknowledged that the health effects of e-cigarettes on youth are not fully understood ([@B43]). In addition to tobacco and cannabis, there is now evidence that adolescents who use inhalants are at increased risk of psychotic disorders ([@B44]) suggesting that adolescence is the developmental period where adverse neuropsychiatric outcomes from psychoactive substances are most likely to occur. There is substantial though not conclusive evidence that the association between tobacco smoking and SSD is causal and may well be a result of the effects of nicotine on multiple neurotransmitter systems. Therefore, policy makers must be cautious when developing regulations for the availability of e-cigarettes, nicotine replacement therapy products and smokeless tobacco. Similarly, health practitioners who recommend e-cigarettes or smokeless tobacco products as a safe alternative to smoking need to consider the findings of the studies identified in this review, especially when providing advice to adolescents.

It is essential that future well designed observational studies are undertaken examining the risk of SSDs in those who use e-cigarettes, particularly in adolescence. A major challenge is the low prevalence of SSD. Recruiting samples large enough to examine the association between e-cigarettes and SSD will take many years. Previous longitudinal research has shown positive associations between cannabis, tobacco and alcohol use and psychotic experiences (PE) which are proxy markers for psychosis risk. PE have the advantage of being higher in prevalence compared to SSD thereby reducing the required sample size to identify associations. Schizophrenia endophenotypes may also have a role to inform the association between nicotine exposure through e-cigarettes and risk of SSD. Previous research has shown that smoking tobacco modulates the association between polymorphisms of transcription factor 4 and reduced sensory gating, an endophenotype of schizophrenia suggesting that the smoking of tobacco might play a role in early information processing deficits in schizophrenia ([@B45]). Use of research paradigms such as PE and endophenotypes PE would expedite research into the association between e-cigarette use and SSD risk. Further research is urgently needed to determine if nicotine is causally associated with incident SSD. In the interim, it is important that policy makers consider the available evidence between tobacco smoking and risk of schizophrenia when evaluating the potential health consequences that might arise from community access to e-cigarettes.
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